COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -- | 464.00K | -12.04M | 1.03M | 2.14M |
| Total Depreciation and Amortization | -- | 2.10M | 806.00K | 2.08M | 2.08M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -2.85M | 16.00K | -883.00K | -464.00K |
| Change in Net Operating Assets | -- | 2.28M | -759.00K | 335.00K | 372.00K |
| Cash from Operations | -- | 1.98M | -11.98M | 2.56M | 4.13M |
| Capital Expenditure | -- | -1.44M | -632.00K | -1.34M | -802.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 26.04M | 0.00 | 0.00 | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -8.00K | 547.00K | -8.00K | -8.00K |
| Cash from Investing | -- | 24.59M | -85.00K | -1.34M | -810.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -488.00K | -213.00K | -432.00K | -424.00K |
| Issuance of Common Stock | -- | 13.00K | -- | 13.00K | 14.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -475.00K | -213.00K | -419.00K | -410.00K |
| Foreign Exchange rate Adjustments | -- | -59.00K | 177.00K | 188.00K | 351.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | 26.04M | -12.10M | 984.00K | 3.26M |